GSK PLC

GSK plc completes Pfizer exit from ViiV Healthcare, boosts its stake and executes a £2,000‑pence share buy‑back—optimising capital, governance, and shareholder value.

GSK’s first‑quarter approvals in China—Exdensur for severe asthma and bepirovirsen for hepatitis B—promise cost‑effective, value‑based therapies that boost clinical outcomes while easing payer budgets.

GSK’s rising oncology sales, FDA‑approved companion diagnostic and new value‑based contracts boost its precision‑medicine strategy, while a focused regulatory hub and cost‑efficiency plans keep the pharma group on a path to robust cash flow and shar…

GSK’s latest share‑buyback and strategic pipeline moves show how a pharma giant balances market access, patent cliffs, and high‑margin R&D to protect shareholder value amid volatile macro‑economic conditions.

GSK PLC expands its global therapeutic reach with approvals for bepirovirsen in Japan, priority reviews in China and Japan, and robust Cabenuva data for adolescents—showcasing safety‑focused, market‑driven progress across infectious, liver, and rare…

GSK’s new siRNA partnership and Bora manufacturing extension promise pipeline resilience, cost savings, and a strong ROI, positioning the company ahead of rivals in the growing RNA therapeutics market.

GSK PLC’s analyst upgrades reveal why investors see steady growth: robust earnings, diverse portfolio, cost cuts, and a strong pipeline that outpaces peers like Pfizer and Novartis.

GSK PLC tops Q4 earnings, driven by specialty HIV and respiratory drugs, aims for £40B sales by 2031, and plans strategic acquisitions to grow.

GSK cuts up to 350 R&D jobs yet boosts investment, showing its focus on oncology, immunology and rare‑disease breakthroughs amid portfolio gains and regulatory wins.

GSK’s $2.5 bn acquisition of Rapt Therapeutics gives the pharma giant a Phase IIb anti‑IgE allergy therapy, boosting its portfolio, opening high‑growth markets, and positioning it for value‑based reimbursement success.